This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine

This study has been completed.
Thrasher Research Fund
Information provided by:
Boston Children’s Hospital Identifier:
First received: October 9, 2007
Last updated: April 30, 2008
Last verified: December 2007
The purpose of this study is to compare the efficacy and safety of influenza vaccine in patients with inflammatory bowel disease (IBD) on immunosuppressive therapy with IBD patients on aminosalicylates and healthy historical controls.

Condition Intervention
Inflammatory Bowel Disease (IBD) Immunosuppressed or Non-Immunosuppressed Influenza Vaccine Antibody Titers Seroprotective Titers Other: blood draw

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Impact of Immunosuppression in Patients With Inflammatory Bowel Disease on Responsiveness to Influenza Vaccine

Resource links provided by NLM:

Further study details as provided by Boston Children’s Hospital:

Primary Outcome Measures:
  • seroprotection rate [ Time Frame: 3-8 weeks after vaccination ]

Secondary Outcome Measures:
  • vaccine-associated adverse events [ Time Frame: up to 8 weeks after vaccination ]
  • antibody titer levels [ Time Frame: 3-8 weeks after vaccination ]

Biospecimen Retention:   Samples Without DNA
Blood for seroprotection rate and antibody titers

Enrollment: 146
Study Start Date: October 2007
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
IBD patients on immunosuppressive therapy
Other: blood draw
drawing blood for seroprotection and antibody titers to the 3 strains of influenza on Day 1 and Month 1 (3-8 weeks)
IBD patients on non-immunosuppressive therapy (e.g., aminosalicylates, antibiotics) or on no medications
Other: blood draw
drawing blood for seroprotection and antibody titers to the 3 strains of influenza on Day 1 and Month 1 (3-8 weeks)

  Show Detailed Description


Ages Eligible for Study:   5 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients aged 5 years and older with documented inflammatory bowel disease (Crohn's disease, ulcerative colitis, indeterminate colitis)

Inclusion Criteria:

  1. Crohn's disease, ulcerative colitis, or indeterminate colitis diagnosed by standard clinical, radiographic, endoscopic, and histologic criteria.
  2. Age 5 years and older
  3. Actively or previously followed by a gastroenterologist at Children's Hospital Boston
  4. On non-immunosuppressants (aminosalicylates, antibiotics, or no medications) and/or immunosuppressants (steroids, immunomodulators, TNF-alpha inhibitors) for the past 30 days. Standard concomitant medications (e.g. antihistamines, acetaminophen) will be allowed.

Exclusion Criteria:

  1. History of bleeding disorder that would make hematoma likely (eg hemophilia, von Willebrand's disease)
  2. Received influenza vaccination during the current influenza season
  3. Contraindications to the influenza vaccine (such as severe allergic reaction to prior influenza vaccine)
  4. Fever within 48 hr prior to injection
  5. Receipt of another vaccination within 2 days of influenza vaccine dose (and no other vaccines planned for 2 days after influenza vaccine)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00542776

United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Boston Children’s Hospital
Thrasher Research Fund
Principal Investigator: Ying Lu, MD Boston Children’s Hospital
  More Information


Responsible Party: Ying Lu, MD, Children's Hospital Boston Identifier: NCT00542776     History of Changes
Other Study ID Numbers: 07-09-0345
Study First Received: October 9, 2007
Last Updated: April 30, 2008

Keywords provided by Boston Children’s Hospital:
inflammatory bowel disease (IBD)
immunosuppressed or non-immunosuppressed
influenza vaccine
antibody titers
seroprotective titers
vaccine-associated adverse events

Additional relevant MeSH terms:
Influenza, Human
Intestinal Diseases
Inflammatory Bowel Diseases
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Gastrointestinal Diseases
Digestive System Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on August 21, 2017